Semaphorin 3G (SEMA3G) is a highly selective marker of cerebral amyloid angiopathy
Biomarkers of cerebral amyloid angiopathy (CAA) are critically needed. We recently identified semaphorin 3G (SEMA3G) as a novel protein selectively enriched in CAA. Here, we aimed to determine if SEMA3G was a selective marker of CAA in a large cohort of human brain tissue spanning multiple neurodegenerative diseases and three brain regions, and to determine if SEMA3G directly interacts with…
Cerebral amyloid angiopathy (CAA) is a condition that requires effective biomarkers, and researchers have recently identified semaphorin 3G (SEMA3G) as a potential novel marker. To investigate SEMA3G's selectivity in CAA, a team of scientists conducted a study using a large collection of human brain tissue from various diseases and brain regions.
Through multiplexed immunofluorescence, the researchers discovered that SEMA3G accumulated only in CAA+ blood vessels across all cases examined. Furthermore, they found that SEMA3G specifically associated with Aβ40, AβpS8, and AβpE3, but not with Aβ42. To validate their findings, they employed Thioflavin T assays and transmission electron microscopy, which revealed that SEMA3G directly interacted with Aβ and slowed its aggregation in vitro. The effect was more pronounced for Aβ40 compared to Aβ42.
In conclusion, this study demonstrates that SEMA3G is a highly specific marker of CAA in the brain, providing valuable insight into the underlying mechanisms of this condition.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
